RecruitingNCT06333561

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Studying Fibrolamellar hepatocellular carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Sun Yat-sen University
Principal Investigator
Feng Duan, MD, MD
Chinese PLA General Hospital
Intervention
Hepatic arterial infusion chemotherapy(procedure)
Enrollment
300 enrolled
Eligibility
18-75 years · All sexes
Timeline
20212025

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06333561 on ClinicalTrials.gov

Other trials for Fibrolamellar hepatocellular carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Fibrolamellar hepatocellular carcinoma

← Back to all trials